TABLE 2.
Expression and replication in GFP cell lines
| Construct | Expressiona | Replicationb |
|---|---|---|
| pFRT.myc | NAc | 5.5 (1.0) |
| pFRT.TRE-GFP, forward, uninduced | 84 (19) | 1 (0.4) |
| pFRT.TRE-GFP, forward, induced | 783 (25) | 0.8 (0.6) |
| pFRT.myc.TRE-GFP, forward, uninduced | 6 (1) | 14.5 (1.5) |
| pFRT.myc.TRE-GFP, forward, induced | 46 (2) | 3.5 (1.0) |
| pFRT.myc.TRE-GFP, forward, uninduced, + α | NA | 4 (1.0) |
| pFRT.myc.TRE-GFP, forward, induced, + α | NA | 6.5 (1.5) |
| pFRT.myc.TRE-GFP, reverse, uninduced | 3 (1) | 19 (1.0) |
| pFRT.myc.TRE-GFP, reverse, induced | 7 (1) | 5.5 (0.8) |
| pFRT.myc.TRE-GFP, reverse, uninduced, + α | NA | 13.5 (1.0) |
| pFRT.myc.TRE-GFP, reverse, induced, + α | NA | 13.0 (1.0) |
a
GFP mRNA was measured by reverse transcription real-time PCR and is expressed as copies (standard deviation) per 1,000 copies of GAPDH. Data are from Figure 3.
b
Nascent strand abundance (standard deviation) at STS-UV was measured as described in Materials and Methods and is expressed for each construct relative to the nascent strand abundance at STS-54.8 of the human β-globin locus (1, 2). “α” denotes α-amanitin treatment. Data are from Figure 5.
c
NA, not assayed.